Provider barriers in uptake of biosimilars: case study on filgrastim
Am J Manag Care. 2023 May 1;29(5):e155-e158. doi: 10.37765/ajmc.2023.89363.ABSTRACTIn this article, we used administrative claims data from the OptumLabs Data Warehouse and American Hospital Association Annual Survey data to examine associations between hospital characteristics and uptake of biosimilar granulocyte colony-stimulating factor treatments. We found that 340B-participating hospitals and non-rural referral center (RRC) hospitals that reported owning rural health clinics were less likely to administer the lower-cost biosimilars, whereas the opposite was true for hospitals that are RRCs. To our knowledge, our study...
Source: The American Journal of Managed Care - May 25, 2023 Category: Health Management Authors: Jessica Chang Pinar Karaca-Mandic Ronald S Go Stephen Schondelmeyer Daniel Weisdorf Molly Moore Jeffery Source Type: research
Provider barriers in uptake of biosimilars: case study on filgrastim
Am J Manag Care. 2023 May 1;29(5):e155-e158. doi: 10.37765/ajmc.2023.89363.ABSTRACTIn this article, we used administrative claims data from the OptumLabs Data Warehouse and American Hospital Association Annual Survey data to examine associations between hospital characteristics and uptake of biosimilar granulocyte colony-stimulating factor treatments. We found that 340B-participating hospitals and non-rural referral center (RRC) hospitals that reported owning rural health clinics were less likely to administer the lower-cost biosimilars, whereas the opposite was true for hospitals that are RRCs. To our knowledge, our study...
Source: The American Journal of Managed Care - May 25, 2023 Category: Health Management Authors: Jessica Chang Pinar Karaca-Mandic Ronald S Go Stephen Schondelmeyer Daniel Weisdorf Molly Moore Jeffery Source Type: research
Provider barriers in uptake of biosimilars: case study on filgrastim
Am J Manag Care. 2023 May 1;29(5):e155-e158. doi: 10.37765/ajmc.2023.89363.ABSTRACTIn this article, we used administrative claims data from the OptumLabs Data Warehouse and American Hospital Association Annual Survey data to examine associations between hospital characteristics and uptake of biosimilar granulocyte colony-stimulating factor treatments. We found that 340B-participating hospitals and non-rural referral center (RRC) hospitals that reported owning rural health clinics were less likely to administer the lower-cost biosimilars, whereas the opposite was true for hospitals that are RRCs. To our knowledge, our study...
Source: The American Journal of Managed Care - May 25, 2023 Category: Health Management Authors: Jessica Chang Pinar Karaca-Mandic Ronald S Go Stephen Schondelmeyer Daniel Weisdorf Molly Moore Jeffery Source Type: research
Provider barriers in uptake of biosimilars: case study on filgrastim
Am J Manag Care. 2023 May 1;29(5):e155-e158. doi: 10.37765/ajmc.2023.89363.ABSTRACTIn this article, we used administrative claims data from the OptumLabs Data Warehouse and American Hospital Association Annual Survey data to examine associations between hospital characteristics and uptake of biosimilar granulocyte colony-stimulating factor treatments. We found that 340B-participating hospitals and non-rural referral center (RRC) hospitals that reported owning rural health clinics were less likely to administer the lower-cost biosimilars, whereas the opposite was true for hospitals that are RRCs. To our knowledge, our study...
Source: The American Journal of Managed Care - May 25, 2023 Category: Health Management Authors: Jessica Chang Pinar Karaca-Mandic Ronald S Go Stephen Schondelmeyer Daniel Weisdorf Molly Moore Jeffery Source Type: research
Provider barriers in uptake of biosimilars: case study on filgrastim
Am J Manag Care. 2023 May 1;29(5):e155-e158. doi: 10.37765/ajmc.2023.89363.ABSTRACTIn this article, we used administrative claims data from the OptumLabs Data Warehouse and American Hospital Association Annual Survey data to examine associations between hospital characteristics and uptake of biosimilar granulocyte colony-stimulating factor treatments. We found that 340B-participating hospitals and non-rural referral center (RRC) hospitals that reported owning rural health clinics were less likely to administer the lower-cost biosimilars, whereas the opposite was true for hospitals that are RRCs. To our knowledge, our study...
Source: The American Journal of Managed Care - May 25, 2023 Category: Health Management Authors: Jessica Chang Pinar Karaca-Mandic Ronald S Go Stephen Schondelmeyer Daniel Weisdorf Molly Moore Jeffery Source Type: research
Provider barriers in uptake of biosimilars: case study on filgrastim
Am J Manag Care. 2023 May 1;29(5):e155-e158. doi: 10.37765/ajmc.2023.89363.ABSTRACTIn this article, we used administrative claims data from the OptumLabs Data Warehouse and American Hospital Association Annual Survey data to examine associations between hospital characteristics and uptake of biosimilar granulocyte colony-stimulating factor treatments. We found that 340B-participating hospitals and non-rural referral center (RRC) hospitals that reported owning rural health clinics were less likely to administer the lower-cost biosimilars, whereas the opposite was true for hospitals that are RRCs. To our knowledge, our study...
Source: The American Journal of Managed Care - May 25, 2023 Category: Health Management Authors: Jessica Chang Pinar Karaca-Mandic Ronald S Go Stephen Schondelmeyer Daniel Weisdorf Molly Moore Jeffery Source Type: research
Provider barriers in uptake of biosimilars: case study on filgrastim
Am J Manag Care. 2023 May 1;29(5):e155-e158. doi: 10.37765/ajmc.2023.89363.ABSTRACTIn this article, we used administrative claims data from the OptumLabs Data Warehouse and American Hospital Association Annual Survey data to examine associations between hospital characteristics and uptake of biosimilar granulocyte colony-stimulating factor treatments. We found that 340B-participating hospitals and non-rural referral center (RRC) hospitals that reported owning rural health clinics were less likely to administer the lower-cost biosimilars, whereas the opposite was true for hospitals that are RRCs. To our knowledge, our study...
Source: The American Journal of Managed Care - May 25, 2023 Category: Health Management Authors: Jessica Chang Pinar Karaca-Mandic Ronald S Go Stephen Schondelmeyer Daniel Weisdorf Molly Moore Jeffery Source Type: research
Provider barriers in uptake of biosimilars: case study on filgrastim
Am J Manag Care. 2023 May 1;29(5):e155-e158. doi: 10.37765/ajmc.2023.89363.ABSTRACTIn this article, we used administrative claims data from the OptumLabs Data Warehouse and American Hospital Association Annual Survey data to examine associations between hospital characteristics and uptake of biosimilar granulocyte colony-stimulating factor treatments. We found that 340B-participating hospitals and non-rural referral center (RRC) hospitals that reported owning rural health clinics were less likely to administer the lower-cost biosimilars, whereas the opposite was true for hospitals that are RRCs. To our knowledge, our study...
Source: The American Journal of Managed Care - May 25, 2023 Category: Health Management Authors: Jessica Chang Pinar Karaca-Mandic Ronald S Go Stephen Schondelmeyer Daniel Weisdorf Molly Moore Jeffery Source Type: research
Provider barriers in uptake of biosimilars: case study on filgrastim
Am J Manag Care. 2023 May 1;29(5):e155-e158. doi: 10.37765/ajmc.2023.89363.ABSTRACTIn this article, we used administrative claims data from the OptumLabs Data Warehouse and American Hospital Association Annual Survey data to examine associations between hospital characteristics and uptake of biosimilar granulocyte colony-stimulating factor treatments. We found that 340B-participating hospitals and non-rural referral center (RRC) hospitals that reported owning rural health clinics were less likely to administer the lower-cost biosimilars, whereas the opposite was true for hospitals that are RRCs. To our knowledge, our study...
Source: The American Journal of Managed Care - May 25, 2023 Category: Health Management Authors: Jessica Chang Pinar Karaca-Mandic Ronald S Go Stephen Schondelmeyer Daniel Weisdorf Molly Moore Jeffery Source Type: research
Provider barriers in uptake of biosimilars: case study on filgrastim
Am J Manag Care. 2023 May 1;29(5):e155-e158. doi: 10.37765/ajmc.2023.89363.ABSTRACTIn this article, we used administrative claims data from the OptumLabs Data Warehouse and American Hospital Association Annual Survey data to examine associations between hospital characteristics and uptake of biosimilar granulocyte colony-stimulating factor treatments. We found that 340B-participating hospitals and non-rural referral center (RRC) hospitals that reported owning rural health clinics were less likely to administer the lower-cost biosimilars, whereas the opposite was true for hospitals that are RRCs. To our knowledge, our study...
Source: The American Journal of Managed Care - May 25, 2023 Category: Health Management Authors: Jessica Chang Pinar Karaca-Mandic Ronald S Go Stephen Schondelmeyer Daniel Weisdorf Molly Moore Jeffery Source Type: research
Provider barriers in uptake of biosimilars: case study on filgrastim
Am J Manag Care. 2023 May 1;29(5):e155-e158. doi: 10.37765/ajmc.2023.89363.ABSTRACTIn this article, we used administrative claims data from the OptumLabs Data Warehouse and American Hospital Association Annual Survey data to examine associations between hospital characteristics and uptake of biosimilar granulocyte colony-stimulating factor treatments. We found that 340B-participating hospitals and non-rural referral center (RRC) hospitals that reported owning rural health clinics were less likely to administer the lower-cost biosimilars, whereas the opposite was true for hospitals that are RRCs. To our knowledge, our study...
Source: The American Journal of Managed Care - May 25, 2023 Category: Health Management Authors: Jessica Chang Pinar Karaca-Mandic Ronald S Go Stephen Schondelmeyer Daniel Weisdorf Molly Moore Jeffery Source Type: research
Provider barriers in uptake of biosimilars: case study on filgrastim
Am J Manag Care. 2023 May 1;29(5):e155-e158. doi: 10.37765/ajmc.2023.89363.ABSTRACTIn this article, we used administrative claims data from the OptumLabs Data Warehouse and American Hospital Association Annual Survey data to examine associations between hospital characteristics and uptake of biosimilar granulocyte colony-stimulating factor treatments. We found that 340B-participating hospitals and non-rural referral center (RRC) hospitals that reported owning rural health clinics were less likely to administer the lower-cost biosimilars, whereas the opposite was true for hospitals that are RRCs. To our knowledge, our study...
Source: The American Journal of Managed Care - May 25, 2023 Category: Health Management Authors: Jessica Chang Pinar Karaca-Mandic Ronald S Go Stephen Schondelmeyer Daniel Weisdorf Molly Moore Jeffery Source Type: research
Provider barriers in uptake of biosimilars: case study on filgrastim
Am J Manag Care. 2023 May 1;29(5):e155-e158. doi: 10.37765/ajmc.2023.89363.ABSTRACTIn this article, we used administrative claims data from the OptumLabs Data Warehouse and American Hospital Association Annual Survey data to examine associations between hospital characteristics and uptake of biosimilar granulocyte colony-stimulating factor treatments. We found that 340B-participating hospitals and non-rural referral center (RRC) hospitals that reported owning rural health clinics were less likely to administer the lower-cost biosimilars, whereas the opposite was true for hospitals that are RRCs. To our knowledge, our study...
Source: The American Journal of Managed Care - May 25, 2023 Category: Health Management Authors: Jessica Chang Pinar Karaca-Mandic Ronald S Go Stephen Schondelmeyer Daniel Weisdorf Molly Moore Jeffery Source Type: research
Provider barriers in uptake of biosimilars: case study on filgrastim
Am J Manag Care. 2023 May 1;29(5):e155-e158. doi: 10.37765/ajmc.2023.89363.ABSTRACTIn this article, we used administrative claims data from the OptumLabs Data Warehouse and American Hospital Association Annual Survey data to examine associations between hospital characteristics and uptake of biosimilar granulocyte colony-stimulating factor treatments. We found that 340B-participating hospitals and non-rural referral center (RRC) hospitals that reported owning rural health clinics were less likely to administer the lower-cost biosimilars, whereas the opposite was true for hospitals that are RRCs. To our knowledge, our study...
Source: The American Journal of Managed Care - May 25, 2023 Category: Health Management Authors: Jessica Chang Pinar Karaca-Mandic Ronald S Go Stephen Schondelmeyer Daniel Weisdorf Molly Moore Jeffery Source Type: research
